The impact of prostate-transurethral resection on erectile dysfunction in benign prostatic hyperplasia

Background: Erectile dysfunction (ED) after a prostate-transurethral resection (P-TUR) is one of the problems in the treatment of benign prostatic hyperplasia (BPH) that may affect the quality of life in middle-aged and older men. The aim of this study was to investigate the impact of P-TUR on ED in BPH patients.

Methods: This study was conducted on 83 patients suffering from BPH that underwent a P-TUR. Clinically, testosterone levels, prostatic-specific antigen (PSA) levels, and prostate volume were measured before the P-TUR. Erectile function was measured prior to the P-TUR, as well as at 1 and 3 months after the P-TUR using the International Index of Erectile Function (IIEF). Suitability test of the model was done in a structural equation. Data were analyzed using the chi-square (χ²) test by Analysis of Moment Structure (AMOS) software version 21.

Results: The effects of PSA to IIEF before, 1 month after, and 3 months after P-TUR were 0.116, 0.084, and 0.097, respectively. The effects of body mass index to IIEF before, 1 month after, and 3 months after P-TUR were 0.180, 0.066, and 0.164, respectively. The effects of prostate volume to IIEF before, 1 month after, and 3 months after P-TUR were 0.049, 0.004, and 0.011, respectively. The effects of testosterone to IIEF before, 1 month after, and 3 months after P-TUR were −0.029, −0.453, and −0.415, respectively. The effects of age to IIEF before, 1 month after, and 3 months after P-TUR were −0.444, 0.921, and 0.911, respectively.

Conclusion: There was a significant improvement of erectile function in patients that underwent P-TUR who previously had preoperative ED, especially 3 months after the surgery.

Keywords: age, prostate volume, testosterone, PSA, IIEF, improvement

Introduction

Clinical benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS) in elderly men is one of the most common diseases.1,2 The parameters of the disease progression include prostate-specific antigen (PSA), older age, prostate volume, International Prostate Symptom Score, and reduced urine flow.3 The gold standard technique for surgical treatment of clinical BPH with benign prostate obstruction is the transurethral resection of the prostate (P-TUR). P-TUR is a combined visual and surgical instrument (using a resectoscope) that is inserted through the urethra. An electrical loop cuts away excess prostate tissue to improve urine flow. P-TUR is a minimally invasive surgery using high-frequency resection that allows better visualization of the prostate with less intraoperative bleeding when compared to classical open surgery.4,5

Both BPH and P-TUR have been associated with erectile dysfunction (ED). ED is defined as the inability to achieve or maintain an erection sufficient for satisfactory sexual performance.6,7 P-TUR has been associated with ED, but the extent of the association can vary depending on the study's design.8

Methods:

The present study was conducted at the Department of Urology, Faculty of Medicine, Udayana University, Denpasar, Indonesia. We included 83 patients with BPH who underwent P-TUR. The patients' clinical characteristics were recorded, including age, prostate volume, testosterone, PSA, IIEF, and other relevant data.

Results:

The effects of PSA to IIEF before, 1 month after, and 3 months after P-TUR were 0.116, 0.084, and 0.097, respectively. The effects of body mass index to IIEF before, 1 month after, and 3 months after P-TUR were 0.180, 0.066, and 0.164, respectively. The effects of prostate volume to IIEF before, 1 month after, and 3 months after P-TUR were 0.049, 0.004, and 0.011, respectively. The effects of testosterone to IIEF before, 1 month after, and 3 months after P-TUR were −0.029, −0.453, and −0.415, respectively. The effects of age to IIEF before, 1 month after, and 3 months after P-TUR were −0.444, 0.921, and 0.911, respectively.

Conclusion:

There was a significant improvement of erectile function in patients that underwent P-TUR who previously had preoperative ED, especially 3 months after the surgery.

Keywords:

age, prostate volume, testosterone, PSA, IIEF, improvement

Introduction

Clinical benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS) in elderly men is one of the most common diseases.2,3 The parameters of the disease progression include prostate-specific antigen (PSA), older age, prostate volume, International Prostate Symptom Score, and reduced urine flow.3 The gold standard technique for surgical treatment of clinical BPH with benign prostate obstruction is the transurethral resection of the prostate (P-TUR). P-TUR is a combined visual and surgical instrument (using a resectoscope) that is inserted through the urethra. An electrical loop cuts away excess prostate tissue to improve urine flow. P-TUR is a minimally invasive surgery using high-frequency resection that allows better visualization of the prostate with less intraoperative bleeding when compared to classical open surgery.4,5

Both BPH and P-TUR have been associated with erectile dysfunction (ED). ED is defined as the inability to achieve or maintain an erection sufficient for satisfactory sexual performance.6,7 P-TUR has been associated with ED, but the extent of the association can vary depending on the study's design.8
sexual performance. Association between BPH and ED is very complex and the incidence increases with age. Prevalence of ED in Asia ranges widely from 2.0% to 81.8%, while in Indonesia, it ranges from 11% to 80%. The differences between countries are thought to be caused by sociocultural, economic, demographic factor, and a lack of data for evaluation of ED.

Several factors play an important role in the appearance of ED, like aging, diabetes, obesity, smoking, alcohol, cardiovascular, and neurological pathologies. All of these factors trigger ED by a mechanism of endothelial dysfunction. Psychology also plays a role in ED. Men with BPH usually have decreased libido and find it difficult to achieve or maintain a penile erection.

The impact of P-TUR on ED is still controversial and conflicting. Recent studies have shown a negative impact and others have shown improvement in sexual function in patients suffering from ED. The assessment of male sexual function is commonly performed by an internationally validated questionnaire known as the International Index of Erectile Function (IIEF-5). IIEF-5 contains five questions related to penile function and has a maximum score of 25. The total score was then used to define the patient with severe, moderate, mild to moderate, mild, and normal erectile function.

The aim of this study was to assess the impact of P-TUR on IIEF before, after 1 month, and 3 months after P-TUR.

Materials and methods
This is a retrospective study conducted from June to November 2016, involving 89 patients that underwent P-TUR in four hospitals in Bali Island, Indonesia (Sanglah, Surya Husadha, Dharma Yadnya, and Balimed hospitals). This study was approved by the committee of ethical research of Udayana University. The consecutive sampling method was used for this study. All patients have provided written informed consent to be included in this study. The inclusion criteria were patients with BPH aged, 50–80 years old, and underwent P-TUR. The exclusion criteria include patients with diabetes mellitus, external genital anomalies, bladder stone, and neurogenic bladder, and the presence of neurological deficit.

Age, testosterone, the volume of prostate, body mass index (BMI), and PSA were defined as observed exogenous variables. Blood testosterone level was measured 1 day before surgery at 8:00–10:00 am local time. Prostate volume was measured prior to surgery using the transrectal ultrasound (TRUS) method. The score of IIEF before P-TUR, after 1 month of P-TUR, and after 3 months of P-TUR were defined as observed endogenous variables.

The results from the microscopic prostate pathological examinations were used to define BPH. There were six patients who came up with carcinoma of the prostate, and they were excluded from the study. The characteristics of the subjects were presented using descriptive statistics, and data was analyzed using SEM (Structural Equation Modeling) program of Analysis of Moment Structure (AMOS) software version 21.

Suitability test of the model (Goodness of Fit) is done in a structural equation. The suitability tests used in this study were chi-square (χ²), probability level, root mean square error of approximation (RMSE), Tucker-Levis Index (TLI), Comparative Fit Index (CFI), Expected Cross Validation Index (ECVI), and Modified ECVI (MECVI). All tests indicated that this was a fit model.

Results
A total of 83 patients were enrolled in this study. The mean age of the subjects was 64.4±8.2 years. The age, BMI, and testosterone levels were normally distributed and presented in mean ± SD, while other variables that were not normally distributed were presented in median. The characteristic of the subjects involved is displayed in Table 1.

The effects between observed exogenous variables (PSA, BMI, prostate volume, testosterone, and age) against observed IIEF pre-P-TUR, 1-month post-P-TUR, and 3 months post-P-TUR were calculated for direct, indirect, and total effects (Table 2–4). Table 5 summarizes Table 2–4 showing that the effect of each observed exogenous variables to observed endogenous variables. The effects of P-TUR were shown where the effects between pre-P-TUR and

Table 1 Characteristics of the study subjects (N=83)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Mean ± SD</th>
<th>Median (min-max)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>64.4±8.2</td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>22.9±3.1</td>
<td></td>
</tr>
<tr>
<td>Testosterone (ng/dL)</td>
<td>412.4±177.1</td>
<td>39.2 (20.7–97.5)</td>
</tr>
<tr>
<td>Prostate volume (mL)</td>
<td></td>
<td>6.5 (0.2–60.4)</td>
</tr>
<tr>
<td>PSA (ng/mL)</td>
<td></td>
<td>15 (4–25)</td>
</tr>
<tr>
<td>IIEF Pre P-TUR</td>
<td></td>
<td>15 (4–25)</td>
</tr>
<tr>
<td>IIEF Post P-TUR 1M</td>
<td></td>
<td>16 (4–25)</td>
</tr>
<tr>
<td>IIEF Post P-TUR 3M</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: IIEF Pre P-TUR = IIEF before P-TUR, IIEF Post P-TUR 1M = IIEF 1 month after P-TUR, IIEF Post P-TUR 3M = IIEF 3 months after P-TUR.
Abbreviations: BMI, body mass index; PSA, prostatic-specific antigen; IIEF, International Index of Erectile Function; P-TUR, prostate-transurethral resection.
Table 2 Effects between observed exogenous variables to IIEF before P-TUR procedure

<table>
<thead>
<tr>
<th></th>
<th>PSA (ng/mL)</th>
<th>BMI (kg/m²)</th>
<th>Prostate volume (mL)</th>
<th>Testosterone level (ng/dL)</th>
<th>Age (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct effects</td>
<td>0.116</td>
<td>0.180</td>
<td>0.049</td>
<td>−0.029</td>
<td>−0.444</td>
</tr>
<tr>
<td>Indirect effects</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
<td>0.000</td>
</tr>
<tr>
<td>Total effects</td>
<td>0.116</td>
<td>0.180</td>
<td>0.049</td>
<td>−0.029</td>
<td>−0.444</td>
</tr>
</tbody>
</table>

Notes: *Chi-square test.
Abbreviations: PSA, prostatic specific antigen; BMI, body mass index; IIEF, International Index of Erectile Function; P-TUR, prostate-transurethral resection.

Table 3 Effects between observed exogenous variables to IIEF after 1 month of P-TUR

<table>
<thead>
<tr>
<th></th>
<th>PSA (ng/mL)</th>
<th>BMI (kg/m²)</th>
<th>Prostate volume (mL)</th>
<th>Testosterone level (ng/dL)</th>
<th>Age (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct effects</td>
<td>−0.023</td>
<td>0.000</td>
<td>−0.041</td>
<td>0.046</td>
<td>−0.045</td>
</tr>
<tr>
<td>Indirect effects</td>
<td>0.107</td>
<td>0.166</td>
<td>0.046</td>
<td>−0.027</td>
<td>−0.409</td>
</tr>
<tr>
<td>Total effects</td>
<td>0.084</td>
<td>0.166</td>
<td>0.004</td>
<td>0.019</td>
<td>−0.453</td>
</tr>
</tbody>
</table>

Notes: *Chi-square test; IIEF (1)=IIEF before P-TUR; IIEF (2)=IIEF 1 month after P-TUR.
Abbreviations: PSA, prostatic specific antigen; BMI, body mass index; IIEF, International Index of Erectile Function; P-TUR, prostate-transurethral resection.

Table 4 Effects between observed exogenous variables to IIEF after 3 months of P-TUR

<table>
<thead>
<tr>
<th></th>
<th>PSA (ng/mL)</th>
<th>BMI (kg/m²)</th>
<th>Prostate volume (mL)</th>
<th>Testosterone level (ng/dL)</th>
<th>Age (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct effects</td>
<td>0.014</td>
<td>0.000</td>
<td>0.007</td>
<td>0.006</td>
<td>0.034</td>
</tr>
<tr>
<td>Indirect effects</td>
<td>0.083</td>
<td>0.164</td>
<td>0.004</td>
<td>0.019</td>
<td>−0.449</td>
</tr>
<tr>
<td>Total effects</td>
<td>0.097</td>
<td>0.164</td>
<td>0.011</td>
<td>0.025</td>
<td>−0.415</td>
</tr>
</tbody>
</table>

Notes: IIEF (1)=IIEF before P-TUR; IIEF (2)=IIEF 1 month after P-TUR; IIEF (3)=IIEF 3 months after P-TUR.
Abbreviations: PSA, prostatic specific antigen; BMI, body mass index; IIEF, International Index of Erectile Function; P-TUR, prostate-transurethral resection.

Table 5 Effects between observed exogenous variables against observed endogenous variables in BPH patients

<table>
<thead>
<tr>
<th></th>
<th>PSA →</th>
<th>IIEF (1)</th>
<th>IIEF (2)</th>
<th>IIEF (3)</th>
<th>BMI →</th>
<th>IIEF (1)</th>
<th>IIEF (2)</th>
<th>IIEF (3)</th>
<th>PROST →</th>
<th>IIEF (1)</th>
<th>IIEF (2)</th>
<th>IIEF (3)</th>
<th>TESTOST →</th>
<th>IIEF (1)</th>
<th>IIEF (2)</th>
<th>IIEF (3)</th>
<th>AGE →</th>
<th>IIEF (1)</th>
<th>IIEF (2)</th>
<th>IIEF (3)</th>
<th>IIEF (1) →</th>
<th>IIEF (2)</th>
<th>IIEF (3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct effects</td>
<td>0.116</td>
<td>0.180</td>
<td>0.049</td>
<td>−0.029</td>
<td>−0.029</td>
<td>0.007</td>
<td>0.007</td>
<td>−0.027</td>
<td>−0.027</td>
<td>−0.029</td>
<td>0.004</td>
<td>0.046</td>
<td>0.006</td>
<td>−0.044</td>
<td>−0.045</td>
<td>−0.444</td>
<td>0.921</td>
<td>0.989</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indirect effects</td>
<td>−0.023</td>
<td>−</td>
<td>−0.41</td>
<td>−0.041</td>
<td>−0.027</td>
<td>−</td>
<td>−</td>
<td>−0.409</td>
<td>−0.409</td>
<td>−0.444</td>
<td>−0.453</td>
<td>0.911</td>
<td>0.097</td>
<td>−0.415</td>
<td>−0.499</td>
<td>0.911</td>
<td>0.989</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total effects</td>
<td>0.116</td>
<td>0.180</td>
<td>0.049</td>
<td>−0.029</td>
<td>−0.029</td>
<td>0.004</td>
<td>0.004</td>
<td>−0.027</td>
<td>−0.027</td>
<td>−0.029</td>
<td>0.004</td>
<td>0.019</td>
<td>0.019</td>
<td>−0.444</td>
<td>−0.453</td>
<td>−0.444</td>
<td>0.921</td>
<td>0.989</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: IIEF (1)=IIEF before P-TUR; IIEF (2)=IIEF 1 month after P-TUR; IIEF (3)=IIEF 3 months after P-TUR.
Abbreviations: PSA, prostatic-specific antigen; BMI, body mass index; PROST, prostate volume; TESTOST, testosterone level; AGE, age (years); IIEF, International Index of Erectile Function; P-TUR, prostate-transurethral resection.
Discussion
This study shows a significant negative correlation between age and IIEF before P-TUR ($p=0.444$). Age is strongly associated with ED in many other studies. With an increased age, the IIEF value tends to decline. This can be caused by an aging process that affects human morphology and physiology that play a role in the development of sexual dysfunction.

The main mechanism includes vascular and physiological alteration. Vascular alteration is a vascular endothelial change with a regulatory function such as proliferative process, vascular tone regulation, perfusion maintenance, and inflammatory response. In a normal aging process, they will result in an accumulation of endothelial dysfunction. Most ED cases are caused by vascular alteration, and the severity of ED is related to severe endothelial dysfunction with some well-known risk factors, including hypertension, hyperlipidemia, atherosclerosis, and diabetes.

ED is also related to morphological changes based on alteration of every structure within corpus cavernosum resulting in reduced muscle tone. Aging has reportedly caused a decrease in the number of smooth muscle fibers. Smooth muscle cells play a role in contracting and relaxing of the corpus cavernosum. It has been reported that good erectile function depends on an adequate amount of the smooth muscle cells. However, in a recent study of univariable and multivariable linear regression analysis, age was found to be the only risk factor associated with newly-reported ED in 12 months after P-TUR ($P<0.001$). Patients who were older than 65 years old had a higher risk of developing ED after P-TUR ($P<0.001$) compared with that ≤65 years old.

While the goals for BPH treatment is to reduce symptoms, it should be realized that the treatment can negatively affect the patient’s quality of life. P-TUR may cause retrograde ejaculation, but the impact of P-TUR on ED remains unclear. The mechanism of a post-operative penile flaccidity is thought due to a neuropraxia or direct thermal injury on the erectile nerve that runs just beneath the prostatic capsule. This may result in increased apoptosis and fibrosis of corpus cavernosum that leads to poor oxygenation of the cavernous due to arterial damage during the surgical procedure. Shorbagy et al found that P-TUR carries a risk in developing post-operative ED at an estimated 25.5% and the other recent studies showed the incidence between 4% and 35%. In this study, 80.7% of our subjects developed ED before the treatment and they were related to the progress of LUTS. This is similar to the study by Oelke et al that found 70% of men with BPH were associated with ED. The discrepancy between the prevalence of ED was perhaps determined by multiple factors such as socioeconomic, educational level, or sociocultural differences, which prevent people from understanding more about the disease and seeking appropriate treatment.

The total effect of 0.921 (Table 3) showed an improved significance between the correlation of the IIEF score before P-TUR and 1 month after P-TUR. The erectile ability was improved within a month and we presumed that this improvement was caused by a relief of obstructive symptoms or LUTS. This may also be related to axon regeneration and endothelial recovery after the treatment. A neuropraxia-type axonal injury will heal in a few days to 3 months, while an axonotmesis-type axonal injury, the recovery takes longer than the neuropraxia-type. In a condition where 20–30% of the axon is damaged, collateral branching is the primary mechanism of recovery. It begins at the first 4 days to 4 months following the injury. The P-TUR did not adversely affect sexual function. Preoperative ED can be improved by P-TUR and long-term sexual function is maintained after P-TUR.

In addition, we also found an improved significant correlation between IIEF after 1 month P-TUR and 3 months post-P-TUR. This may be related to a psychological factor, that when patients found it difficult to urinate due to BPH, they suffer from conditions that create stress and affect sexual desire. After P-TUR, the mental stress detaches and the libido becomes normal, and patients would feel their erectile ability improved.

Considering the number of variables that affect the IIEF score, we were also looking for a correlation between the variables. Very few studies determined the correlation between prostate volume and PSA. In this study, we measured prostate volume by the TRUS method. One of the parameters in detecting prostate enlargement is plasma PSA. PSA is a protein produced by the normal cells in the prostate, which the amount of the secretions can vary caused by conditions such as inflammation, benign prostatic enlargement or malignancy, digital rectal exam (DRE) or catheter instrumentation. PSA is an organ-specific, but not disease-specific, biomarker.

This study shows a significant two-way correlation between both variables (Table 3). Prostatic enlargement is proportional to the volume of the prostate. In other
words, the larger the prostate volume is, the higher the PSA level. Park et al. found significant correlation between PSA and prostate volume in a Korean man ($r=0.514; P<0.005$). Several studies showed that the correlation between PSA and prostate volume would determine the progression of the prostate enlargement.\textsuperscript{19,20}

Erection process is clearly androgen-dependent. Testosterone plays an important role in increasing the prevalence of male erectile function because aging and castration cause a decline of serum testosterone level. Testosterone stimulates nitric oxide (NO) synthase which leads penile vasodilatation by the production of endothelial NO. Deficiency of testosterone level could lead to a reduction of penile strength.\textsuperscript{21} In this study, testosterone has no significant correlation to another exogenous variable (age, prostate volume, BMI and PSA) in our BPH patients.

Current evidence suggests that BMI is one of the determining factors of ED and occurrence of ED is usually associated with higher BMI from the direct mechanism in the penile vessel by reducing the production of NO synthase and loss of tissue compliance. Obesity also impacts the sexual life by decreasing the desire and the performance of the intercourse.\textsuperscript{22} There was no significant correlation between BMI to exogenous variables in our study.

A small sample size is the limitation of this study. A similar study with larger sample size needs to be done in the future to confirm these findings. Other sexual hormones like estrogen, prolactin, luteinizing hormone, and follicle stimulating hormone, need to be measured too, as well as the urine maximum flow (Qmax) and the post-void residual urine test.

**Conclusion**

ED is a common condition in BPH patients. It is very important to assess the presence of ED on BPH patients before the surgery to compare sexual function before and after the treatment.

P-TUR as a gold standard treatment of BPH has no negative influence on the quality of erection. In fact, we found that it showed a significant improvement of erectile function on patients who previously had preoperative ED, especially 3 months after the surgery. We also found that aging is the most powerful variable compared to other variables that affect erectile function of our patients.

**Disclosure**

The authors report no conflicts of interest in relation to this study.

## References


